PE20070820A1 - Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas - Google Patents
Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasasInfo
- Publication number
- PE20070820A1 PE20070820A1 PE2006001256A PE2006001256A PE20070820A1 PE 20070820 A1 PE20070820 A1 PE 20070820A1 PE 2006001256 A PE2006001256 A PE 2006001256A PE 2006001256 A PE2006001256 A PE 2006001256A PE 20070820 A1 PE20070820 A1 PE 20070820A1
- Authority
- PE
- Peru
- Prior art keywords
- lipase
- methanone
- triazolo
- pyridin
- quality
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X =C(-R)-, =N-, EN LA QUE AL MENOS 1 O A LO SUMO 2 X ES/SON =N-; W ES -(C=O)-, -(S=O)-, -(SO2)-; R ES H, HALOGENO, HALOALQUILO C1-C3, ALQUILOXI C1-C3, ENTRE OTROS; R1 ES ALQUILO C5-C16, CICLOALQUILO C5-C12, BICICLO, TRIFLUOROMETOXI, ENTRE OTROS; R2 ES H, ALQUILO C4-C12, O R1 Y R2 PUEDEN FORMAR UN SISTEMA DE ANILLO DE 4 A 7 MIEMBROS, MONOCICLICO, SATURADO O PARCIALMENTE INSATURADO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5-CLORO-[1,2,3]TRIAZOLO[4,5-b]PIRIDIN-1-IL)-(3,4-DIHIDRO-1H-ISOQUINOLIN-2-IL)-METANONA; (5-CLORO-[1,2,3]TRIAZOLO[4,5-b]PIRIDIN-1-IL)-(3,4-DIHIDRO-1H-ISOQUINOLIN-2-IL)-METANONA; (4-METILPIPERIDIN-1-IL)-[1,2,3]TRIAZOLO[4,5-c]PIRIDIN-1-IL-METANONA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LIPASA SENSIBLE A HORMONAS O DE LIPASA ENDOTELIAL UTILES EN TRASTORNOS DEL METABOLISMO DE LOS ACIDOS GRASOS Y TRASTORNOS DE UTILIZACION DE GLUCOSA, SINDROME METABOLICO, DIABETES, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005049954A DE102005049954A1 (de) | 2005-10-19 | 2005-10-19 | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070820A1 true PE20070820A1 (es) | 2007-09-04 |
Family
ID=37487398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001256A PE20070820A1 (es) | 2005-10-19 | 2006-10-17 | Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas |
Country Status (26)
Country | Link |
---|---|
US (2) | US7718669B2 (es) |
EP (1) | EP1940838B1 (es) |
JP (1) | JP2009512649A (es) |
KR (1) | KR20080057299A (es) |
CN (1) | CN101291932A (es) |
AR (1) | AR058095A1 (es) |
AU (1) | AU2006303551A1 (es) |
BR (1) | BRPI0617712A2 (es) |
CA (1) | CA2625442A1 (es) |
CR (1) | CR9851A (es) |
DE (1) | DE102005049954A1 (es) |
DO (1) | DOP2006000227A (es) |
EC (1) | ECSP088376A (es) |
HN (1) | HN2006035237A (es) |
IL (1) | IL190715A0 (es) |
MA (1) | MA29857B1 (es) |
MY (1) | MY140514A (es) |
NO (1) | NO20082159L (es) |
NZ (1) | NZ567574A (es) |
PE (1) | PE20070820A1 (es) |
RU (1) | RU2008119435A (es) |
TN (1) | TNSN08178A1 (es) |
TW (1) | TW200800987A (es) |
UY (1) | UY29878A1 (es) |
WO (1) | WO2007045392A1 (es) |
ZA (1) | ZA200802369B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
ES2614090T3 (es) | 2005-12-29 | 2017-05-29 | Celtaxsys, Inc. | Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa |
FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
FR2915199B1 (fr) * | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
FR2915197B1 (fr) | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010044441A1 (ja) | 2008-10-17 | 2010-04-22 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 |
BR122013027950A2 (pt) * | 2008-12-24 | 2019-12-10 | BIAL PORTELA & Cª S A | compostos farmacêuticos |
JP5791150B2 (ja) | 2009-12-15 | 2015-10-07 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有するオキサジアゾール誘導体 |
CN103096893B (zh) | 2010-06-04 | 2016-05-04 | 阿尔巴尼分子研究公司 | 甘氨酸转运体-1抑制剂、其制备方法及其用途 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
AU2014249168B2 (en) | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
MX2015011677A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
EP3495357B1 (en) | 2013-03-14 | 2021-05-05 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
BR112015022227A2 (pt) | 2013-03-14 | 2017-07-18 | Celtaxsys Inc | inibidores de leucotrieno a4 hidrolase |
US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
RU2678196C2 (ru) | 2013-03-14 | 2019-01-24 | Селтакссис, Инк. | Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы |
US9637450B2 (en) | 2013-03-14 | 2017-05-02 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
US9580422B2 (en) * | 2013-10-22 | 2017-02-28 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
KR102429220B1 (ko) | 2014-04-30 | 2022-08-04 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 치환 4-페닐피페리딘, 그 제조 및 사용 |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE |
CN117126134A (zh) * | 2022-05-20 | 2023-11-28 | 中国科学院上海药物研究所 | 新型四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
DE102004005172A1 (de) * | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
-
2005
- 2005-10-19 DE DE102005049954A patent/DE102005049954A1/de not_active Withdrawn
-
2006
- 2006-10-12 RU RU2008119435/04A patent/RU2008119435A/ru not_active Application Discontinuation
- 2006-10-12 CN CNA200680039028XA patent/CN101291932A/zh active Pending
- 2006-10-12 JP JP2008535941A patent/JP2009512649A/ja not_active Abandoned
- 2006-10-12 AU AU2006303551A patent/AU2006303551A1/en not_active Abandoned
- 2006-10-12 NZ NZ567574A patent/NZ567574A/en not_active IP Right Cessation
- 2006-10-12 MY MYPI20081120A patent/MY140514A/en unknown
- 2006-10-12 WO PCT/EP2006/009856 patent/WO2007045392A1/de active Application Filing
- 2006-10-12 EP EP06806215A patent/EP1940838B1/de active Active
- 2006-10-12 KR KR1020087009354A patent/KR20080057299A/ko not_active Application Discontinuation
- 2006-10-12 BR BRPI0617712-3A patent/BRPI0617712A2/pt not_active IP Right Cessation
- 2006-10-12 CA CA002625442A patent/CA2625442A1/en not_active Abandoned
- 2006-10-17 TW TW095138144A patent/TW200800987A/zh unknown
- 2006-10-17 PE PE2006001256A patent/PE20070820A1/es not_active Application Discontinuation
- 2006-10-17 AR ARP060104518A patent/AR058095A1/es not_active Application Discontinuation
- 2006-10-17 DO DO2006000227A patent/DOP2006000227A/es unknown
- 2006-10-18 HN HN2006035237A patent/HN2006035237A/es unknown
- 2006-10-19 UY UY29878A patent/UY29878A1/es not_active Application Discontinuation
-
2008
- 2008-03-13 ZA ZA200802369A patent/ZA200802369B/xx unknown
- 2008-03-28 CR CR9851A patent/CR9851A/es not_active Application Discontinuation
- 2008-04-08 MA MA30824A patent/MA29857B1/fr unknown
- 2008-04-08 IL IL190715A patent/IL190715A0/en unknown
- 2008-04-09 US US12/099,922 patent/US7718669B2/en not_active Expired - Fee Related
- 2008-04-17 EC EC2008008376A patent/ECSP088376A/es unknown
- 2008-04-18 TN TNP2008000178A patent/TNSN08178A1/en unknown
- 2008-05-08 NO NO20082159A patent/NO20082159L/no not_active Application Discontinuation
-
2010
- 2010-03-25 US US12/731,225 patent/US20100190801A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20080057299A (ko) | 2008-06-24 |
RU2008119435A (ru) | 2009-11-27 |
TNSN08178A1 (en) | 2009-10-30 |
AR058095A1 (es) | 2008-01-23 |
MA29857B1 (fr) | 2008-10-03 |
CR9851A (es) | 2008-07-29 |
MY140514A (en) | 2009-12-31 |
BRPI0617712A2 (pt) | 2011-08-02 |
DE102005049954A1 (de) | 2007-05-31 |
EP1940838B1 (de) | 2012-08-22 |
CA2625442A1 (en) | 2007-04-26 |
DOP2006000227A (es) | 2007-05-15 |
IL190715A0 (en) | 2008-11-03 |
JP2009512649A (ja) | 2009-03-26 |
HN2006035237A (es) | 2010-03-11 |
NZ567574A (en) | 2010-03-26 |
WO2007045392A1 (de) | 2007-04-26 |
AU2006303551A1 (en) | 2007-04-26 |
ZA200802369B (en) | 2009-01-28 |
US20100190801A1 (en) | 2010-07-29 |
UY29878A1 (es) | 2007-05-31 |
EP1940838A1 (de) | 2008-07-09 |
US20090030011A1 (en) | 2009-01-29 |
CN101291932A (zh) | 2008-10-22 |
TW200800987A (en) | 2008-01-01 |
NO20082159L (no) | 2008-05-08 |
ECSP088376A (es) | 2008-05-30 |
US7718669B2 (en) | 2010-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070820A1 (es) | Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas | |
HRP20050641A2 (en) | New carboxylic acids and the esters thereof, pharmaceutical compositions containing these compounds and processes for the preparation thereof | |
PE20060210A1 (es) | 8-[3-amino-piperidin-1-il]-xantinas como inhibidores de dpp-iv | |
PE20070367A1 (es) | Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa | |
NO20081569L (no) | Administrasjon av dipeptidylpeptildaseinhibitorer | |
WO2007083188A3 (en) | Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative | |
PE20090049A1 (es) | Derivados de piridopirimidina como moduladores de la actividad de pde 4 | |
PE20070491A1 (es) | Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina | |
EA201170771A1 (ru) | Органические соединения | |
RS53574B1 (en) | PYROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | |
CL2010001486A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras. | |
MX2007012438A (es) | Forma cristalina de un compuesto de quinolinona-carboxamida. | |
PE20091398A1 (es) | Compuestos biciclicos conteniendo nitrogeno activos en condiciones de dolor cronicas | |
PE20081159A1 (es) | Inhibidores de las quinasas y metodos para su utilizacion | |
SI2041133T1 (sl) | Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki | |
PE20130346A1 (es) | Compuestos heterociclicos fusionados | |
BRPI0517846A (pt) | azaindolcarboxamidas | |
NO20076680L (no) | Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter | |
MA29554B1 (fr) | Nouveaux derives d'amide d'acide piperidine carboxylique | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
NO20075044L (no) | Nytt salt av kinuclidinderivat | |
PE20070010A1 (es) | Penemes triciclicos de 6-alquilideno como inhibidores de beta-lactasas clase d | |
PE20091182A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-CARBOXAMIDAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
WO2007085760A3 (fr) | Solution anti-infectieuse comprenant un compose de type pyrido(3,2,1-ij)-benzoxadiazine | |
DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |